195 results on '"Kristensen, Salome"'
Search Results
52. Intake of marine n-3 polyunsaturated fatty acids and the risk of rheumatoid arthritis: protocol for a cohort study using data from the Danish Diet, Cancer and Health cohort and Danish health registers
53. Incidence and risk factors of COVID-19 in patients with vasculitis in the first year of the pandemic: a Danish nationwide cohort study
54. Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus: A Nationwide Cohort Study from Denmark
55. Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial
56. Risk of flare after tapering or withdrawal of biologic/targeted synthetic disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or axial spondyloarthritis: a systematic review and meta-analysis.
57. Are fatty acids associated with disease activity and biomarkers in patients with psoriatic arthritis? Data from a multicenter clinical trial
58. Tapering and Withdrawal of Biologics or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in Patients with Inflammatory Arthritis:A Systematic Review and Meta-Analyses of Randomised Trials
59. Digital Solution for Collection of Patient-reported Outcome Measures in Patients with Systemic Lupus Erythematosus: A Randomised, Crossover, Agreement Study
60. Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus:A nationwide Danish cross-sectional study
61. Patient-reported outcome measures in systemic lupus erythematosus by a web-based application:A randomized, crossover, agreement study
62. The effect of transcutaneous vagus nerve stimulation in patients with polymyalgia rheumatica
63. Incidence of COVID-19 Hospitalisation in Patients with Systemic Lupus Erythematosus:A Nationwide Cohort Study from Denmark
64. Effect of n-3 PUFA on extracellular matrix protein turnover in patients with psoriatic arthritis: a randomized, double-blind, placebo-controlled trial
65. Comparative effectiveness of two adalimumab biosimilars in 1318 real-world patients with inflammatory rheumatic disease mandated to switch from originator adalimumab: nationwide observational study emulating a randomised clinical trial
66. Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study
67. Is pain associated with premature mortality in patients with psoriatic arthritis? A nested case–control study using the DANBIO Register
68. Patient-reported outcome measures collected via the DANBIO app vs a touchscreen in the outpatient clinic among patients with inflammatory arthritis:A randomised, crossover, agreement study
69. Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4):an observational nationwide study applying linkage between DANBIO and national registries
70. Response to To switch or not to switch':The missing piece in the puzzle of biosimilar literature?' by Scherlinger et al
71. Response to:'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: Possible fallout on non-medical switching' by Cantini and Benucci
72. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark
73. Deep Breathing Increases Heart Rate Variability in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus
74. Hospital contacts due to hepatobiliary adverse events in >5000 patients with inflammatory joint disease treated with originator or biosimilar etanercept (SB4): an observational nationwide study applying linkage between DANBIO and national registries
75. Patient-reported outcome measures in systemic lupus erythematosus by a web-based application: A randomized, crossover, agreement study.
76. Accelerated extracellular matrix remodeling in psoriatic arthritis & value of ECM-related biomarkers
77. To switch or not to switch:Results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
78. Incidence and severeness of COVID-19 hospitalization in patients with inflammatory rheumatic disease: a nationwide cohort study from Denmark.
79. Deep Breathing Increases Heart Rate Variability in Patients With Rheumatoid Arthritis and Systemic Lupus Erythematosus.
80. Smoking associates with distinct clinical phenotypes in patients with systemic lupus erythematosus: a nationwide Danish cross-sectional study.
81. Dosage reduction and discontinuation of biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis: protocol for a pragmatic, randomised controlled trial (the BIOlogical Dose OPTimisation (BIODOPT) trial)
82. FRI0370 ACCELERATED EXTRACELLULAR MATRIX REMODELING IN PSORIATIC ARTHRITIS & VALUE OF ECM-RELATED BIOMARKERS
83. Response to ‘‘To switch or not to switch’: the missing piece in the puzzle of biosimilar literature?’ by Scherlinger et al
84. Response to: ‘Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching’ by Cantini and Benucci
85. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry
86. Clinical outcomes from a nationwide non-medical switch from originator to biosimilar etanercept in patients with inflammatory arthritis after 5 months follow-up:Results from The DANBIO Registry
87. One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept:an Observational Study from the Danish Danbio Registry
88. Marine n-3 Polyunsaturated Fatty Acids in Psoriatic Arthritis – Inflammation and Cardiac Autonomic and Hemodynamic Function
89. A nationwide non-medical switch from originator infliximab to biosimilar CT-P13 in 802 patients with inflammatory arthritis: 1-year clinical outcomes from the DANBIO registry
90. The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: a randomised, double-blind, placebo-controlled trial
91. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry.
92. Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis:Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry
93. 7.7 THE EFFECT OF MARINE N-3 POLYUNSATURATED FATTY ACIDS ON CARDIAC AUTONOMIC AND HEMODYNAMIC FUNCTION IN PATIENTS WITH PSORIATIC ARTHRITIS: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
94. Assessment of enthesitis in patients with psoriatic arthritis using clinical examination and ultrasound
95. The effect of marine n-3 polyunsaturated fatty acids on cardiac autonomic and hemodynamic function in patients with psoriatic arthritis: A randomised, double-blind, placebo-controlled trial
96. Response to: 'Mandatory, cost-driven switching from originator etanercept to its biosimilar SB4: possible fallout on non-medical switching' by Cantini and Benucci.
97. Response to ''To switch or not to switch': the missing piece in the puzzle of biosimilar literature?' by Scherlinger .
98. One-Year Clinical Outcomes in 1623 Patients with Inflammatory Arthritis Who Switched from Originator to Biosimilar Etanercept - an Observational Study from the Danish Danbio Registry
99. Non-Medical Switch from Originator to Biosimilar Infliximab in Patients with Inflammatory Arthritis - Impact on s-Infliximab and Antidrug-Antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry
100. Abstract Supplement ACR Convergence 2023.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.